Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension
Standard
Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension. / Neumann, Johannes Tobias; Ewen, Sebastian; Mortensen, Kai; Nef, Holger; Zeller, Tanja; Ojeda, Francisco; Sydow, Karsten; Mahfoud, Felix; Böhm, Michael; Hamm, Christian; Dörr, Oliver; Blankenberg, Stefan.
in: BIOMARK MED, Jahrgang 10, Nr. 8, 08.2016, S. 841-851.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effects of renal denervation on heart failure biomarkers and blood pressure in patients with resistant hypertension
AU - Neumann, Johannes Tobias
AU - Ewen, Sebastian
AU - Mortensen, Kai
AU - Nef, Holger
AU - Zeller, Tanja
AU - Ojeda, Francisco
AU - Sydow, Karsten
AU - Mahfoud, Felix
AU - Böhm, Michael
AU - Hamm, Christian
AU - Dörr, Oliver
AU - Blankenberg, Stefan
PY - 2016/8
Y1 - 2016/8
N2 - AIM: This multicenter study investigated the effect of renal denervation therapy (RDN) on the heart failure related biomarkers NT-proBNP, ST-2, galectin-3 and hs-TnI.PATIENTS & METHODS: We included 157 patients with resistant hypertension undergoing RDN. Blood sampling was performed before and 6 months after RDN.RESULTS: Six months after RDN systolic blood pressure (BP) was reduced by 24 mmHg. Biomarker concentrations were not changed after RDN, except a small increase of hs-TnI by 0.3 pg/ml. In individuals with high baseline BP, we observed a BP reduction of 45 mmHg and a decrease of hs-TnI concentrations by 1.2 pg/ml.CONCLUSION: In this multicenter analysis RDN did significantly reduce systolic BP. However, NT-proBNP, ST-2, galectin-3 and hs-TnI did not correspond to BP reduction 6 months after RDN.
AB - AIM: This multicenter study investigated the effect of renal denervation therapy (RDN) on the heart failure related biomarkers NT-proBNP, ST-2, galectin-3 and hs-TnI.PATIENTS & METHODS: We included 157 patients with resistant hypertension undergoing RDN. Blood sampling was performed before and 6 months after RDN.RESULTS: Six months after RDN systolic blood pressure (BP) was reduced by 24 mmHg. Biomarker concentrations were not changed after RDN, except a small increase of hs-TnI by 0.3 pg/ml. In individuals with high baseline BP, we observed a BP reduction of 45 mmHg and a decrease of hs-TnI concentrations by 1.2 pg/ml.CONCLUSION: In this multicenter analysis RDN did significantly reduce systolic BP. However, NT-proBNP, ST-2, galectin-3 and hs-TnI did not correspond to BP reduction 6 months after RDN.
KW - Aged
KW - Biomarkers/blood
KW - Blood Pressure/physiology
KW - Echocardiography
KW - Female
KW - Galectin 3/blood
KW - Heart Failure/complications
KW - Humans
KW - Hypertension/complications
KW - Hypertrophy, Left Ventricular/diagnostic imaging
KW - Interleukin-1 Receptor-Like 1 Protein/blood
KW - Kidney/innervation
KW - Male
KW - Middle Aged
KW - Natriuretic Peptide, Brain/blood
KW - Peptide Fragments/blood
KW - Pulse Wave Analysis
KW - Troponin I/blood
U2 - 10.2217/bmm-2016-0098
DO - 10.2217/bmm-2016-0098
M3 - SCORING: Journal article
C2 - 27428075
VL - 10
SP - 841
EP - 851
JO - BIOMARK MED
JF - BIOMARK MED
SN - 1752-0363
IS - 8
ER -